JP6124417B2 - 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤 - Google Patents

抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤 Download PDF

Info

Publication number
JP6124417B2
JP6124417B2 JP2014518384A JP2014518384A JP6124417B2 JP 6124417 B2 JP6124417 B2 JP 6124417B2 JP 2014518384 A JP2014518384 A JP 2014518384A JP 2014518384 A JP2014518384 A JP 2014518384A JP 6124417 B2 JP6124417 B2 JP 6124417B2
Authority
JP
Japan
Prior art keywords
thrombomodulin
cancer
seq
amino acid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014518384A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013179910A1 (ja
Inventor
川畑　篤史
篤史 川畑
鈴木　秀明
秀明 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Kindai University
Original Assignee
Asahi Kasei Pharma Corp
Kindai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp, Kindai University filed Critical Asahi Kasei Pharma Corp
Priority to JP2014518384A priority Critical patent/JP6124417B2/ja
Publication of JPWO2013179910A1 publication Critical patent/JPWO2013179910A1/ja
Application granted granted Critical
Publication of JP6124417B2 publication Critical patent/JP6124417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014518384A 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤 Active JP6124417B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014518384A JP6124417B2 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012125316 2012-05-31
JP2012125316 2012-05-31
PCT/JP2013/063743 WO2013179910A1 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP2014518384A JP6124417B2 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017071200A Division JP6279788B2 (ja) 2012-05-31 2017-03-31 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Publications (2)

Publication Number Publication Date
JPWO2013179910A1 JPWO2013179910A1 (ja) 2016-01-18
JP6124417B2 true JP6124417B2 (ja) 2017-05-10

Family

ID=49673113

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014518384A Active JP6124417B2 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP2017071200A Active JP6279788B2 (ja) 2012-05-31 2017-03-31 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP2018005582A Active JP6427284B2 (ja) 2012-05-31 2018-01-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017071200A Active JP6279788B2 (ja) 2012-05-31 2017-03-31 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP2018005582A Active JP6427284B2 (ja) 2012-05-31 2018-01-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Country Status (20)

Country Link
US (1) US10709767B2 (OSRAM)
EP (1) EP2857037B1 (OSRAM)
JP (3) JP6124417B2 (OSRAM)
KR (1) KR101672114B1 (OSRAM)
CN (1) CN104394885B (OSRAM)
AU (1) AU2013268725B2 (OSRAM)
BR (1) BR112014028852A2 (OSRAM)
CA (1) CA2875069C (OSRAM)
DK (1) DK2857037T3 (OSRAM)
ES (1) ES2743767T3 (OSRAM)
HU (1) HUE045997T2 (OSRAM)
IL (1) IL235984B (OSRAM)
IN (1) IN2014DN10075A (OSRAM)
MX (1) MX364934B (OSRAM)
NZ (1) NZ702242A (OSRAM)
PL (1) PL2857037T3 (OSRAM)
PT (1) PT2857037T (OSRAM)
RU (1) RU2595857C2 (OSRAM)
WO (1) WO2013179910A1 (OSRAM)
ZA (1) ZA201408769B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141268A (ja) * 2012-05-31 2017-08-17 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
JP7163906B2 (ja) * 2017-03-31 2022-11-01 東レ株式会社 末梢神経障害の治療剤又は予防剤
US11628147B2 (en) 2017-12-19 2023-04-18 Synergia Life Sciences Pvt. Ltd. Vitamin K2 compositions for the treatment of drug induced neuropathy
MX2021003288A (es) * 2018-09-28 2021-05-13 Asahi Kasei Pharma Corp Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли
AU2022226352A1 (en) * 2021-02-26 2023-09-07 Vibrosense Dynamics Ab Biomarker for prediction of chemotherapy-induced neuropathy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005053A1 (fr) * 1987-01-08 1988-07-14 Asahi Kasei Kogyo Kabushiki Kaisha Peptide servant a accelerer l'activation de la proteine c avec de la thrombine
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
AU643306B2 (en) 1990-06-27 1993-11-11 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
CA2156752C (en) 1993-02-25 1999-01-05 Young Ran Kim Multipurpose reagent system for rapid lysis of whole blood samples
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
EP0763360B1 (en) 1994-04-20 2005-02-16 Asahi Kasei Pharma Corporation Use of thrombomodulin for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
ES2244968T3 (es) 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
ATE298246T1 (de) * 2000-03-28 2005-07-15 Lilly Co Eli Aktiviertes protein c zur behandlung von pankreatitis
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
WO2003061687A1 (fr) * 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation Preparation a concentration elevee de thrombomoduline soluble
SI2017276T1 (sl) * 2003-09-22 2011-05-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
BRPI0607753A2 (pt) * 2005-02-16 2009-10-06 Wyeth Corp método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
JP5453258B2 (ja) 2007-07-13 2014-03-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム カンナビノイド受容体の複素環式モジュレーター
MX2010009026A (es) 2008-02-18 2010-09-24 Esteve Labor Dr Uso de compuestos que se enlazan a los ligandos del receptor sigma para el tratamiento de dolor neuropatico que se desarrolla como una consecuencia de la quimioterapia.
EP2320936A1 (en) * 2008-07-16 2011-05-18 PAION Deutschland GmbH Prevention and treatment of radiation injury
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び／又は治療のための医薬
EP2598126A2 (en) * 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
PT2857037T (pt) 2012-05-31 2019-07-19 Univ Kinki Agente para prevenção e/ou tratamento de dor neuropática periférica causada por fármaco anticanceroso

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141268A (ja) * 2012-05-31 2017-08-17 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP2018095652A (ja) * 2012-05-31 2018-06-21 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
US10709767B2 (en) 2012-05-31 2020-07-14 Kinki University Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Also Published As

Publication number Publication date
MX2014014505A (es) 2015-06-02
KR20150004855A (ko) 2015-01-13
CN104394885B (zh) 2017-06-30
PL2857037T3 (pl) 2019-12-31
RU2595857C2 (ru) 2016-08-27
KR101672114B1 (ko) 2016-11-02
IL235984B (en) 2019-09-26
IN2014DN10075A (OSRAM) 2015-08-21
NZ702242A (en) 2016-03-31
HUE045997T2 (hu) 2020-01-28
EP2857037A1 (en) 2015-04-08
JP6427284B2 (ja) 2018-11-21
EP2857037B1 (en) 2019-06-26
JP2017141268A (ja) 2017-08-17
ZA201408769B (en) 2015-12-23
ES2743767T3 (es) 2020-02-20
WO2013179910A1 (ja) 2013-12-05
PT2857037T (pt) 2019-07-19
EP2857037A4 (en) 2016-04-06
AU2013268725B2 (en) 2017-02-16
US10709767B2 (en) 2020-07-14
CA2875069A1 (en) 2013-12-05
CA2875069C (en) 2018-01-02
AU2013268725A1 (en) 2014-12-18
MX364934B (es) 2019-03-28
BR112014028852A2 (pt) 2018-04-24
JP6279788B2 (ja) 2018-02-14
IL235984A0 (en) 2015-01-29
RU2014148171A (ru) 2016-07-20
JP2018095652A (ja) 2018-06-21
HK1203846A1 (en) 2015-11-06
CN104394885A (zh) 2015-03-04
JPWO2013179910A1 (ja) 2016-01-18
US20150148296A1 (en) 2015-05-28
DK2857037T3 (da) 2019-07-22

Similar Documents

Publication Publication Date Title
JP6279788B2 (ja) 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP6114186B2 (ja) 組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途
PT1390403E (pt) Péptidos derivados a partir de proteínas de filamento neural e a sua utilização médica
CN110869386A (zh) 重组神经生长因子的组合物和方法
KR102806029B1 (ko) 사이클릭 폴리펩타이드, 그것의 제조 방법 및 치료학적 용도
TWI579299B (zh) 去整合蛋白變異體及其醫藥用途
CN110092837B (zh) Uti融合蛋白
JP2011178687A (ja) 造血細胞移植に伴う疼痛の予防および／または治療剤
AU2018382586A1 (en) Recombinant igG Fc multimers for the treatment of neuromyelitis optica
ES2559634T3 (es) Péptidos derivados de NCAM (FGLs)
WO2008120263A2 (en) Prokineticins receptors antagonists, derivatives and uses thereof
JP7245844B2 (ja) 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
HK1203846B (en) Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug
KR20150010957A (ko) 넓은 스펙트럼 erbb 리간드 결합 분자 및 그의 사용 방법
CN118103390A (zh) 工程化TGF-β单体及其使用方法
HK40044828A (en) Medication for alleviating symptoms of peripheral neuropathy caused by anticancer drug and/or suppressing onset of peripheral neuropathy

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170331

R150 Certificate of patent or registration of utility model

Ref document number: 6124417

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250